Basel, Switzerland – Dec 12, 2024, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that a review article was published in Nephron, a leading peer-reviewed journal in nephrology.

The article, titled “Exploring the Critical Role of Tight Junction Proteins in Kidney Disease Pathogenesis” examines the multifaceted roles of tight junction proteins and highlights their contributions to kidney disease mechanisms, emphasizing their impact on disease progression and outcomes.

The review is authored by Pr. David Jayne from the Department of Medicine at the University of Cambridge, UK alongside Alentis contributors including Geoffrey Teixeira, SVP Head of Fibrosis.

Geoffrey Teixeira said, “This review highlights the pivotal role of tight junction proteins, including Claudin-1 (CLDN1), in the progression of kidney disease and their potential for therapeutic development.“

The full article is freely accessible on PubMed.

About Lixudebart (ALE.F02)
Lixudebart is a first-in-class monoclonal antibody developed for liver, lung and kidney fibrosis. The investigational antibody is designed to reverse organ fibrosis by specifically targeting a unique CLDN1 epitope exposed in fibrotic tissue. In Phase 1 single- and multiple-ascending dose studies in healthy volunteers lixudebart was observed to be well tolerated, with no serious safety concerns. Lixudebart is currently being tested in clinical trials for advanced liver fibrosis (NCT05939947) and kidney fibrosis due to ANCA-associated vasculitis (NCT06047171).

About Alentis Therapeutics
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering anti-CLDN1 ADCs and antibodies to modify and reverse the course of select diseases.

Alentis was founded based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). Alentis is headquartered at the pharma-biotech hub in Basel, Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US. Visit www.alentis.ch